Table 2.
Univariate analyses
| PFS | OS | |||
| 2 years | 5 years | 2 years | 5 years | |
| Age at first ASCT, years | ||||
| ≤37.3 (median) | 21.6% (15.1–28.8) | 18.6% (12.5–25.5) | 50.6% (42.1–58.6) | 31.1% (23.4–39) |
| >37.3 | 12.4% (7.5–18.6) | 6.2% (2.8–11.5) | 37.6% (29.5–45.6) | 18.9% (12.4–26.4) |
| P value | 0.006 | 0.03 | ||
| Patient sex | ||||
| Male | 15% (10–21) | 12.4%(7.8–18) | 42.2%(34.5–49.7) | 22.3%(15.9–29.3) |
| Female | 20%(13.1–28) | 13% (7.4–20.2) | 47.3% (37.9–56.1) | 29.4% (21.1–38.2) |
| p value | 0.38 | 0.26 | ||
| Histology | ||||
| Leiomyosarcoma | 9.2% (3.4–18.7) | 7.4% (2.4–16.3) | 34.2% (21.7–47.1) | 18.4% 8.9–30.6) |
| Liposarcoma | 18% (6.6–33.8) | 13.5% (3.9–29.1) | 52.5% (34–68.2) | 20.6% (8.2–36.9) |
| Synovial sarcoma | 22.5% (11.2–36.2) | 15% (6.1–27.6) | 45.3% (29.8–59.6) | 24.9% (12.9–39) |
| Angiosarcoma | 21.3% (9.4–36.4) | 21.3% (9.4–36.4) | 42.9% (25.9–58.9) | 31.8% (16.4–48.4) |
| Other sarcoma | 17.1% (10.9–24.6) | 11.3% (6.3–18.1) | 46.3% (37.3–54.8) | 27.8% (19.8–36.4) |
| P value | 0.49 | 0.63 | ||
| Remission status prior ASCT | ||||
| CR/NED | 32.4% (19.7–45.7) | 25.9% (14.5–38.9) | 63.7% (48.6–75.4) | 43.2% (28.7–56.9) |
| PR+SD | 15.8% (9.9–22.9) | 10.9% (6–17.5) | 40.3% (31.4–49.1) | 20.1% (13.1–28.1) |
| PD | 10.8% (5.1–19.1) | 9.5% (4.2–17.4) | 34.6% (24.1–45.3) | 20.1% (11.8–30.1) |
| P value | 0.001 | 0.002 | ||
| Tumour grading | ||||
| Grade 2 | 16.7% (4.1–36.5) | 5.6% (0.4–22.4) | 71.4% (44.3–87) | 33.3% (11.2–57.6) |
| Grade 3 | 18.5% (10.5–28.3) | 17% (9.4–26.6) | 50.4% (38.1–61.5) | 25.9% (15.9–37) |
| P value | 0.62 | 0.7 | ||
| Preparative regimen | ||||
| Platinum based | 12% (6.2–19.7) | 9.6% (4.5–16.9) | 49.2% (38.2–59.4) | 23% (14.4–32.8) |
| Melphalan based | 24.6% (12.2–39.1) | 21.8% (10.3–36.1) | 47.9% (31.4–62.6) | 36.6% (21.6–51.8) |
| Other | 24.5% (9–43.9) | 12.2% (2.3–31.2) | 39.1% (19–58.8) | 16.8% (4.3–36.2) |
| P value | 0.059 | 0.25 | ||
| Year of ASCT | ||||
| 1996–2000 | 18.3% (12.1–25.5) | 11.8% (6.8–18.4) | 40.8% (32.4–48.9) | 20.6% (14–28) |
| 2001–2005 | 15.1% (8.6–23.3) | 11.5% (5.9–19.2) | 42.8% (32.5–52.7) | 26.1% (16.9–36.2) |
| 2006–2016 | 17.2% (8.9–27.8) | 15.5% (7.6–25.8) | 55% (40.8–67.2) | 35.8% (22.8–49) |
| P value | 0.51 | 0.07 | ||
Bold numbers denote statistical significance (p < 0.05).
ASCT, autologous stem cell transplantation; CR, complete remission; NED, no evidence of disease; OS, overall survival; PFS, progression-free survival; PR, partial remission; SD, stable disease.